Clinical trial · no report yet · Phase 1
FORT-2
Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab in Urothelial Carcinoma
- NCT03473756 ↗
- Completed
- Bayer
- 4 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built. Commentary is thin so far, so the report would be short.
| Channel | Found | |
|---|---|---|
| X threads | 2 | |
| YouTube | 1 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- An International, Multicenter, Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab as First-line Treatment in Cisplatin-ineligible Patients With FGFR-positive Locally Advanced or Metastatic Urothelial Carcinoma
- Phase
- Phase 1
- Status
- Completed
- Conditions
- Urothelial Carcinoma
- Interventions
- Rogaratinib (BAY1163877); Atezolizumab
- Arms
- Rogaratinib + Atezolizumab in Part A · Experimental
- Enrollment
- 37
- Primary outcomes
- Number of Participants With Dose-limiting Toxicities(DLTs)
- Number of Participants With Treatment-emergent Adverse Events (TEAEs)
- Number of Participants With Drug-related TEAEs
- Number of Participants With Treatment-emergent Serious Adverse Events(TESAEs)
- Sponsor
- Bayer
- Start
- May 15, 2018
- Primary completion
- Jul 16, 2021
- Results posted
- Yes
- Registry record
- NCT03473756 · updated Apr 9, 2025
Publications
linked from the registry- Sweis RF, Gajate P, Morales-Barrera R, Lee JL, Necchi A, de Braud F, Penel N, Grunwald V, Maruzzo M, Meran J, Ishida TC, Bao W, Zhou Y, Ellinghaus P, Rosenberg JE. Rogaratinib Plus Atezolizumab in Cisplatin-Ineligible Patients With FGFR RNA-Overexpressing Urothelial Cancer: The FORT-2 Phase 1b Nonrandomized Clinical Trial. JAMA Oncol. 2024 Nov;10(11):1565-1570. doi: 10.1001/jamaoncol.2024.3900. Epub 2024 Sep 19. PubMed 39298147
- Grunewald S, Politz O, Bender S, Heroult M, Lustig K, Thuss U, Kneip C, Kopitz C, Zopf D, Collin MP, Boemer U, Ince S, Ellinghaus P, Mumberg D, Hess-Stumpp H, Ziegelbauer K. Rogaratinib: A potent and selective pan-FGFR inhibitor with broad antitumor activity in FGFR-overexpressing preclinical cancer models. Int J Cancer. 2019 Sep 1;145(5):1346-1357. doi: 10.1002/ijc.32224. Epub 2019 Mar 13. PubMed 30807645